Nivolumab + ipilimumab for head and neck neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Squamous Cell Carcinoma of Head and Neck

Why this status

  1. 18 Apr 2016: Trial registered, NCT02741570
  2. 5 Oct 2016: Trial started, NCT02741570

The trials

NCT02741570: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

State
Completed
Phase
Phase 3
People
947 taking part
Started
5 Oct 2016
Primary completion
10 May 2021
Arms
Nivolumab and Ipilimumab
Results
Posted on the registry
  1. 18 Apr 2016: Trial registered
  2. 5 Oct 2016: Trial started
  3. 3 May 2022: Trial results posted
  4. 22 Sep 2022: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.